
The incoming Trump administration is preparing to shake up how Americans access peptides, a class of drugs increasingly popularized by social media influencers for everything from anti-aging to muscle recovery. On Tuesday, U.S.Health and Human Services Secretary Robert F. Kennedy Jr. announced that the administration aims to establish a new,regulated marketplace for these substances.
The move comes after the Food and Drug Administration (FDA) submitted an “Interim Access Policy” to the White House for review last Thursday. If enacted, the proposal would ease compounding restrictions on six of seven peptides currently under review—including the popular compound BPC-157—allowing specialty pharmacies to mix and dispense them more freely.
“Our objective was to make sure that there is a regulated marketplace, so that what they’re getting is what they claim to be, that is safe, that the factories are inspected,” Kennedy explained during an interview on Fox News’ “The Will Cain Show.” Acknowledging the booming $2 billion to $3 billion peptide market, Kennedy added, “Americans are going to be buying these anyway.”
The push to loosen restrictions has sparked debate within the medical and regulatory communities. In July, outside FDA advisers recommended easing limits on certain peptides, a stance that directly contradicted guidance from the FDA’s own scientists. Agency researchers have maintained that the peptides in question lack sufficient human safety data and clinical studies to definitively establish their efficacy.
Organizations like the Center for Science in the Public Interest have also pushed back, urging the FDA to disregard the advisory committee’s recommendations due to concerns over industry ties among its members. Currently, compounding pharmacies are typically only permitted to mix ingredients of approved medicines in specialized doses, or during periods of official drug shortages.
As the proposal undergoes White House review, the interim policy could provide compounding pharmacies with a temporary safe harbor to produce these short-chain amino acids while a formal, years-long rulemaking process takes shape.

